A retrospective cohort study of coagulation function in patients with liver cirrhosis receiving cefoperazone/sulbactam with and without vitamin K1 supplementation
Authors:
- 13 September 2024
- journal article
- research article
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 46 (6) , 1492-1499
Abstract
Background Cefoperazone/sulbactam is commonly prescribed for the treatment of infected patients with cirrhosis. Aim To investigate the effect of cefoperazone/sulbactam on coagulation in cirrhotic patients and assess the effectiveness of vitamin K1 supplementation in preventing cefoperazone/sulbactam-induced coagulation disorders. Method This retrospective cohort study compared coagulation function in 217 cirrhotic patients who received cefoperazone/sulbactam with and without vitamin K1 supplementation (vitamin K1 group, n = 108; non-vitamin K1 group, n = 109). Propensity score matching (PSM) was used to to reduce confounders’ influence, the SHapley additive exPlanations (SHAP) model to explore the importance of each variable in coagulation disorders. Results In the non-vitamin K1 group, the post-treatment prothrombin time (PT) was 16.5 ± 6.5 s and the activated partial thromboplastin time (aPTT) was 34.8 ± 9.4 s. These were significantly higher than pre-treatment values (PT: 14.6 ± 2.4 s, p = 0.005; aPTT: 30.4 ± 5.9 s, p < 0.001). In the vitamin K1 group, no differences were observed in PT, thrombin time, or platelet count, except for a slightly elevated post-treatment aPTT (37.0 ± 10.4 s) compared to that of pre-treatment (34.4 ± 7.2 s, p = 0.033). The vitamin K1 group exhibited a lower risk of PT prolongation (OR: 0.211, 95% CI: 0.047–0.678) and coagulation disorders (OR: 0.257, 95% CI: 0.126–0.499) compared to that of the non-vitamin K1 group. Propensity score matching analysis confirmed a reduced risk in the vitamin K1 group for prolonged PT (OR: 0.128, 95% CI: 0.007–0.754) and coagulation disorders (OR: 0.222, 95% CI: 0.076–0.575). Additionally, the vitamin K1 group exhibited lower incidences of PT prolongation, aPTT prolongation, bleeding, and coagulation dysfunction compared to the non-vitamin K1 group. Conclusion Cefoperazone/sulbactam use may be linked to a higher risk of PT prolongation and coagulation disorders in cirrhotic patients. Prophylactic use of vitamin K1 can effectively reduce the risk.Keywords
All Related Versions
Funding Information
- Natural Science Foundation of Jiangxi Province (20212BAB206054)
This publication has 21 references indexed in Scilit:
- Cefoperazone-sulbactam and risk of coagulation disorders or bleeding: a retrospective cohort studyExpert Opinion on Drug Safety, 2020
- The Association Between Cephalosporin and Hypoprothrombinemia: A Systematic Review and Meta-AnalysisInternational Journal of Environmental Research and Public Health, 2019
- Cefoperazone/sulbactam therapeutic drug monitoring in patients with liver cirrhosis: Potential factors affecting the pharmacokinetic/pharmacodynamic target attainmentBasic & Clinical Pharmacology & Toxicology, 2019
- Clinical significance of fibrotic, haemostatic and endotoxic changes in patients with liver cirrhosis2018
- Nosocomial and Community-Acquired Spontaneous Bacterial Peritonitis in patients with liver cirrhosis in China: Comparative Microbiology and Therapeutic ImplicationsScientific Reports, 2017
- Cefoperazone/Sulbactam-Induced Abdominal Wall Hematoma and Upper Gastrointestinal Bleeding: A Case Report and Review of the LiteratureDrug Safety - Case Reports, 2016
- Bleeding and Coagulopathies in Critical CareNew England Journal of Medicine, 2014
- Platelet Coagulation-Protein InteractionsSeminars in Thrombosis and Hemostasis, 2004
- Bacterial infection in patients with advanced cirrhosis: a multicentre prospective studyDigestive and Liver Disease, 2001
- Hypoprothrombinemia Associated With Cefoperazone TherapySouthern Medical Journal, 1987